Clinical trialPhase 2Terminated
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
A Phase II Trial of TAS-102 (Lonsurf) in Patients With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma After Progression Through First Line Chemotherapy
- Outcome
- Stopped early. Results posted; single-arm, no comparisoninsufficient time to accrue sufficient subjects before end of funding (Business decision)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 9 November 2017
- Ended
- 26 July 2020
- Enrollment
- 7 participants
- Sites
- 3
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor type
- Academic / other
- Results posted
- 4 February 2021
- Last update
- 4 February 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 4 February 2021
- PFS
- Progression Free Survival (PFS)Treatment Arm: 13.64 (0.14 to 53.86), n = 6Values: mean weeks, Full RangeTime frame: up to 54 weeksNo analysis posted for this outcome (outcome 1)
- Participants
- Treatment Arm: 7 started, 7 completed
- Serious adverse events
- Treatment Arm: 2 of 7Participants with at least one serious adverse event, of those at risk, as posted
4 secondary outcomes
- ORR · Objective Response Rate (ORR)
- Treatment Arm 0/2 [Participants]
- Clinical Benefit Rate
- Treatment Arm 1/2 [Participants]
- Time to Progression (TTP)
- Treatment Arm 15.43 (0.14 to 53.86), n=5 [mean weeks, Full Range]
- OS · Overall Survival (OS)
- Treatment Arm 23.45 (4.71 to 83.29), n=7 [mean weeks, Full Range]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression through or intolerance to first or second line chemotherapy. Trial therapy will consist of TAS-102 (Lonsurf®) 35 mg/m2 to be given orally twice daily on days 1-5 and 8-12 with cycles repeating every 28 days. The primary endpoint is to determine the progression free survival (PFS) in subjects with unresectable pancreatic adenocarcinoma.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Progression Free Survival (PFS) [up to 54 weeks]. Mean, weeks (Full Range). Treatment Arm (n=6): 13.64 (0.14 to 53.86).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Objective Response Rate (ORR) [6 months]. Count Of Participants, Participants. Treatment Arm (n=2): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Clinical Benefit Rate [6 months]. Count Of Participants, Participants. Treatment Arm (n=2): 1.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Time to Progression (TTP) [up to 54 weeks]. Mean, weeks (Full Range). Treatment Arm (n=5): 15.43 (0.14 to 53.86).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival (OS) [up to 84 weeks]. Mean, weeks (Full Range). Treatment Arm (n=7): 23.45 (4.71 to 83.29).